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Introduction
Urea cycle disorders (UCDs) are rare enzymopathies with 
an incidence of 1:35,000 births resulting in ~113 new cases 
per year in the United States.1 They are a significant cause 
of inherited hyperammonemia and afflicted infants, while 
newborns are at substantial risk of recurrent brain injury and 
death. Excessive plasma ammonia is neurotoxic, resulting in 
central nervous system injury including intellectual disabili­
ties, seizures, and loss of psychomotor function1–5; they also 
live with continued nitrogen vulnerability. UCDs result from a 
deficiency in one of six hepatic enzymes or two mitochondrial 
transporters that regulate nitrogen metabolism and urea pro­
duction1–3,5 which are typically classified as an inborn errors 
of metabolism.
Hyperargininemia, or arginase deficiency, is an autoso­
mal recessive disorder that affects the final step of the urea 
cycle. Patients who exhibit hyperargininemia typically pres­
ent, after the neonatal period, with spasticity, seizures, spas­
tic diplegia, and developmental regression, differing from the 
other UCDs.5–8 Arginase 1 (Arg1) is primarily located in the 
liver, hydrolyzing arginine to urea while regenerating orni­
thine to continue the cycle.6,8 Loss of Arg1 activity results 
in an inability to remove nitrogen from arginine, but rarely 
causes symptoms of hyperammonemia. Instead, the cause 
of the pathogenesis of neurological deterioration in arginase 
deficiency is not known and is thought to be due to unique 
biochemical abnormalities such as elevated guanidino com­
pounds, nitric oxide, or glutamine.3,8–10
As there is no completely effective treatment for UCDs, 
the mainstay of therapy is dietary protein restriction, with 
emergency treatments for hyperammonemia consisting of 
dialysis, hemofiltration, and administration of nitrogen scav­
enging drugs.5 Chronic therapy is minimally effective in 
reducing plasma ammonia while control of hyperargininemia 
may delay the onset of symptoms6,8 but may not ultimately 
prevent the progressive and relentless nature of neurocogni­
tive decline. Liver transplantation is the extreme alternative 
to conventional therapies to prevent progression of neuro­
logical injury in UCD patients. However, the demand for liver 
donors far exceeds the supply, and other avenues, such as 
genetic modification and cell replacement therapy, need to be 
explored to treat these disorders.
Since the demonstration that human induced pluripotent 
stem cells (hiPSCs) could be reprogrammed from fibroblasts 
with four transcription factors (Oct4, Sox2, Klf4, and cMyc), 
hiPSCs have emerged as a potential avenue for patient­
specific disease modeling and development of therapy.11–15 
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Urea cycle disorders are incurable enzymopathies that affect nitrogen metabolism and typically lead to hyperammonemia. 
Arginase deficiency results from a mutation in Arg1, the enzyme regulating the final step of ureagenesis and typically 
results in developmental disabilities, seizures, spastic diplegia, and sometimes death. Current medical treatments for urea 
cycle disorders are only marginally effective, and for proximal disorders, liver transplantation is effective but limited by graft 
availability. Advances in human induced pluripotent stem cell research has allowed for the genetic modification of stem cells 
for potential cellular replacement therapies. In this study, we demonstrate a universally-applicable CRISPR/Cas9-based strategy 
utilizing exon 1 of the hypoxanthine-guanine phosphoribosyltransferase locus to genetically modify and restore arginase 
activity, and thus ureagenesis, in genetically distinct patient-specific human induced pluripotent stem cells and hepatocyte-
like derivatives. Successful strategies restoring gene function in patient-specific human induced pluripotent stem cells may 
advance applications of genetically modified cell therapy to treat urea cycle and other inborn errors of metabolism.
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Whereas the difficulty in obtaining primary cell cultures previ­
ously hindered progress of disease research, the ability of 
patient­specific hiPSCs to differentiate into genetically similar 
somatic cell types of various lineages, such as hepatocytes, 
allows for the generation of a substantial quantity of patient­
specific cells.16,17 These hiPSC­derived hepatocytes express 
liver­specific markers such as albumin (ALB), alpha­fetopro­
tein (AFP), and cytokeratin 18 (CK18) as well as functionality 
markers such α1­antitrypsin (AAT) and CYP3A4, demon­
strating their phenotypic similarity to endogenously derived 
hepatocytes.17 Reprogramming patient­specific hiPSCs and 
establishing isogenic and functional derivatives afford the 
advantage of avoiding the ethical controversy of oocyte­
derived embryonic stem cell use and potentially addressing 
the immunogenicity issues for cell replacement therapies.18
In this study, we sought to correct the enzyme deficiency, 
using a universal approach, in multiple arginase­deficient 
hiPSC lines derived from hyperargininemic patients by using 
genome editing technology. We delivered clustered inter­
spaced short palindromic repeats (CRISPR)/Cas9 nickases 
via nucleofection for gene addition of a full­length codon­opti­
mized human arginase 1 cDNA (ArgO) expression cassette 
(Left homologous arm­hEF1a­ArgO­IRES­Puro(R)­Right 
homologous arm (LEAPR)) into Exon 1 of the endogenous 
hypoxanthine­guanine phosphoribosyltransferase (HPRT) 
locus in hiPSCs.19 After targeted insertion and puromycin 
selection (enabled by the LEAPR­derived puromycin N­acetyl­
transferase (PAC)), and with confirmation of the presence of 
the LEAPR cassette in the patient­specific hiPSCs, we dem­
onstrated the restoration of arginase activity in both hiPSCs 
and differentiated hepatocyte­like cells. Results from this 
genetic targeting approach potentially offer a widely applicable 
method to genetically introduce arginase expression in hiP­
SCs derived from hyperargininemic patients and, on a broader 
scale, to other single­enzyme inborn errors of metabolism.
Results
Derivation of patient-specific hiPSCs from arginase-
deficient dermal fibroblasts
We derived genetically­distinct hiPSC lines from dermal 
fibroblasts taken from three patients with hyperargininemia. 
The first disease dermal fibroblast line, AD1, originating from 
a female argininemic patient, was purchased from Coriell 
(GM00954). Two additional dermal fibroblast lines, AD2 and 
AD3, were derived from skin punch biopsies obtained from a 
male and female patient, respectively. The AD dermal fibro­
blasts were successfully reprogrammed to hiPSCs using a 
lentiviral vector expressing a constitutive polycistronic cas­
sette (STEMCCA) encoding the four transcription factors 
OCT4, SOX2, KLF4, and cMyc.11,20,21 Dermal fibroblasts were 
transduced with the STEMCCA lentivirus and were main­
tained in culture for 30 days on mouse embryonic fibroblasts 
before conversion to feeder­free culture conditions. The con­
trol hiPSC line (xc­HUF1), derived from the dermal fibroblasts 
of a healthy adult male was previously established in the lab 
using the same reprogramming methodology.22
AD1, AD2, and AD3 hiPSC lines exhibited normal stem 
cell­like morphology throughout the course of the study. Char­
acterization of the AD hiPSCs included immunophenotyping 
for common pluripotent stem cell markers, alkaline phos­
phatase staining, in vivo teratoma formation, and karyotype 
analysis. AD1, AD2, and AD3 hiPSCs stained positive for 
pluripotency markers: Oct4, NANOG, SSEA­3, SSEA­4, Tra­
1–60, Tra­1–81 and all exhibited positive alkaline phospha­
tase activity (Figure 1a). Normal karyotypic analyses, with 
no genomic abnormalities, were detected through G­band­
ing studies of AD1, AD2, and AD3 hiPSC lines (Figure 1b). 
 Furthermore, AD hiPSCs were collected and injected subcu­
taneously into the hindleg of SCID mice for in vivo teratoma 
analysis. Teratoma sections from AD1, AD2, and AD3 were 
stained with H&E and exhibited formation of gut (endoderm), 
neuroectoderm (ectoderm), and chondrocyte (mesoderm) 
derivatives, demonstrating the ability of our hiPSCs to form 
tissues from all three germ layers (Figure 1c). Additionally, 
the specific arginase mutations were determined for each 
line  (Figure 1d). Characterization of all three diseased hiP­
SCs was compared with nondiseased controls as xc­HUF1 
hiPSCs and demonstrated no difference in pluripotency pro­
file (data not shown).
Design of ArgO and vectors for gene correction of 
hiPSCs
To correct for the mutant Arg1 gene in our patient­derived 
AD hiPSCs, we designed a selectable, full­length codon­
optimized human arginase cDNA (ArgO) expression cas­
sette under the constitutive control of the human elongation 
factor 1α (hEF1α) promoter, referred to as LEAPR, to be 
inserted into Exon 1 of the HPRT locus (Figure 2a). Utilizing 
CRISPR/Cas9 nickases to bind and cleave Exon 1 of HPRT, 
we achieved targeted LEAPR addition into this desired site. 
LEAPR addition and disruption of the HPRT locus allowed for 
secondary positive clonal selection of successful on­target 
integration via resistance to 6­thioguanine (6­TG) treatment. 
Additionally, a puromycin resistance gene encoded within 
the LEAPR construct afforded the ability to utilize an efficient 
dual selection method to isolate a clonal population of cells 
that successfully integrated our vector into the HPRT locus. 
After dual selection with puromycin and 6­TG, AD1, AD2, and 
AD3 hiPSCs maintained normal stem cell­like morphology 
(data not shown).
Evaluation of targeted integration and expression of 
ArgO into corrected hiPSCs
After delivery of the LEAPR construct, we performed experi­
ments to verify correct on­target integration into the AD hiP­
SCs. AD hiPSCs were first dual­selected by two cycles of 
1 μg/ml puromycin treatment for 72 hours followed by 6­TG 
treatment. Dual­resistant cell populations were then clonally 
selected into three subclones each for all AD hiPSC lines. 
To analyze the targeted integration of our donor vector into 
Exon 1 of the HPRT locus, primers were designed to span 
each junction between the endogenous genome and our 
inserted vector. For each junction, one primer was designed 
to bind a region of the genome outside of the homologous 
arm region, and another was designed to bind a sequence 
within our inserted donor vector. Products at both 5′ and 
3′ junction sites demonstrated on­target integration of our 
LEAPR construct in each of three subclones of the corrected 
AD1, AD2, and AD3 hiPSC lines (Figure 2b (for AD1) and 
www.moleculartherapy.org/mtna
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Figure 1  Characterization of arginase deficient (AD) human induced pluripotent stem cells (hiPSCs). (a) Pluripotency of all three AD 
hiPSC lines was measured via immunophenotyping. AD1, AD2, and AD3 subclones were positive for octamer­binding transcription factor­4 
(OCT3/4), homeobox protein nanog (NANOG), stage­specific embryonic antigens 3 (SSEA­3) and 4 (SSEA­4), tumor­related antigens 1–60 
(TRA­1–60) and 1–81 (TRA­1–81), and alkaline phosphatase. AD hiPSCs were compared with a wild type hiPSC line xc­HUF1. (Scale bars 
for all images are 200 μm except alkaline phosphatase which is 500 μm.) (b) AD1, AD2, and AD3 hiPSC lines exhibited normal 46 XX or 46 
XY karyotypes, and (c) demonstrated the ability to form tissues from all three germ layers: gut (endoderm), chondrocytes (mesoderm), and 
neuroectoderm (ectoderm). (Scale bars = 200 μm) (d) Sequencing analysis reveals specific arginase mutations in each line.
AD1 hiPSC AD2 hiPSC AD3 hiPSC
Oct 3/4
Nanog
SSEA-3
SSEA-4
Tra-1-60
Tra-1-81
Alkaline 
phosphatase
a xc-HUF1 hiPSC
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b
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c
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d Line Source Mutation Notes
AD1 Coriell
GM00954
1. c.892 G>C
p.Ala298Pro (A298P)
2. c.61 C>T
p.Arg21Ter (R21X)
Female, Hispanic, 4 years old
1. Heterozygous, disease causing
2. Heterozygous, disease causing
AD2 UCLA 1. c.61 C>T
p.Arg21Ter(R21X)
2. c.709 G>A 
p.Asp237Asn (D237N)
Male, Asian, 23 years old
1. Heterozygous, disease causing 
2. Heterozygous, disease causing
AD3 UCLA 1. c.365 G>A
p.Trp122Ter (W122X)
Female, Hispanic, 52 years old
1. Homozygous, disease causing
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Figure 2 Design and integration of LEAPR expression cassette. (a) Design of the LEAPR construct containing the human codon 
optimized arginase (ArgO). (b) Junction PCR was performed to determine integration of the construct in both wild­type xc­HUF1 and AD1 
hiPSCs in Exon 1 of the HPRT site. (c) Sequencing analysis was performed on the integration of the construct in AD1 hiPSCs at the target site 
(See also Supplementary Figure S1). (d) Genomic integration of LEAPR into the HPRT locus (located on X chromosome) was determined 
for AD1 (female, XX, i.e., two HPRT alleles) by site­specific sequencing at the nuclease target sites (see also Supplementary Figure S2). 
While sequencing confirmed that the other allele of HPRT was not integrated with the donor construct, nuclease activity introduced five genetic 
mutations (noted by red boxes); the fifth resulted in a serine to phenylalanine amino acid change (TCC →TTC). AD, arginase deficient; hiPSCs, 
human induced pluripotent stem cells; HPRT, hypoxanthine­guanine phosphoribosyltransferase; LEAPR, Left homologous arm­hEF1a­ArgO­
IRES­Puro(R)­Right homologous arm; PCR, polymerase chain reaction. 
a
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Supplementary Figure S1 (for AD2 and AD3)). Additionally, 
sequencing analysis of the junction PCR products showed 
the seamless transition between donor vector sequence and 
the endogenous genome sequence of our gene­corrected 
cell lines at both the 5′ and 3′ junctions of our gene cassette 
insert (Figure 2c (for AD1) and Supplementary Figure S1 
(for AD2 and AD3)).
To further characterize the targeted integration of LEAPR 
into the AD hiPSCs, we utilized quantitative reverse tran­
scription­polymerase chain reaction (qRT­PCR) to deter­
mine whether the LEAPR construct integrated into one or 
both HPRT alleles in corrected AD1 and AD3 LEAPR hiP­
SCs and also used sequencing technology to further exam­
ine AD1. As AD1 and AD3 are XX and AD2 is XY, qRT­PCR 
confirmed and demonstrated twice the levels of genomic 
HPRT (gHPRT) in AD1 and AD3 compared with AD2 rela­
tive to genomic glyceraldehyde 3­phosphate dehydrogenase 
(gGAPDH) (Supplementary Figure S2, top). Furthermore, 
qRT­PCR demonstrated equal amplification of ArgO, a unique 
element of the LEAPR construct, relative to gGAPDH dem­
onstrating an equal number of LEAPR integrations through­
out the genomes of AD LEAPR hiPSCs (Supplementary 
 Figure S2, middle). Finally, qRT­PCR demonstrated AD1 and 
AD3 with half the level of ArgO compared with AD2, rela­
tive to HPRT consistent with the integration of 1 LEAPR copy 
per two HPRT alleles in AD1 and AD3 and one LEAPR copy 
per one HPRT allele in AD2 (Supplementary Figure S2, 
bottom). We also sequenced the other HPRT allele of AD1 
which showed lack of integration, confirming that only one 
allele had the integrated donor arginase construct. However, 
because of nuclease activity at that site, five genetic muta­
tions were introduced in the other HPRT allele, the first four 
being silent mutations and the fifth resulting in a serine to 
phenylalanine amino acid change (Figure 2d).
Off­target analysis was performed in AD1 LEAPR hiPSCs 
to determine and quantify potential insertions and deletions 
due to off­target sequence homology for nickases A and B. 
High probability sites for off­target nickase binding for each 
nuclease were determined in silico (probability scores of 
1.37, 0.86, and 0.86 for nickase A and 0.58 for nickase B (out 
of a maximum score of 100)) were examined via sequenc­
ing. Analysis demonstrated 0% insertions and deletions at all 
sites (Supplementary Figure S3a,b).
Arginase levels were examined in the LEAPR­corrected 
hiPSC lines by measuring RNA expression via qRT­PCR and 
functionality via urea production (i.e., restoring ureagenesis). 
After puromycin and 6­TG selection, corrected hiPSCs (n = 
3) expressed significantly higher RNA levels (P < 0.0001) of 
codon optimized arginase compared with wild type arginase 
RNA levels in uncorrected AD hiPSCs, demonstrating on­
target integration and expression in all three corrected hiPSC 
lines. The integration of ArgO increased arginase mRNA lev­
els in AD1, AD2, and AD3 hiPSCs to 57, 92, and 46% (repli­
cates of n = 3 per sample) respectively when compared with 
wild type arginase levels in human fetal liver (Figure 3a (for 
AD1) and Supplementary Figure S4 (for AD2 and AD3)). 
Additionally, all corrected AD hiPSCs exhibited a significant 
increase (P < 0.0001) in urea production itself (i.e., functional 
activity) when compared with their uncorrected counterparts. 
Functionality of corrected AD1 hiPSCs increased to 102% 
(P = 0.0212) of that measured in human fetal liver lev­
els  (Figure 3b for AD1). Varying degrees of recovery were 
observed in AD1, AD2, and AD3 corrected lines; however, the 
lowest recorded recovery level was still 71% of the primary 
fetal liver (Figure 3b and Supplementary Figure S5 for AD2 
and AD3). Taken together, these data demonstrate (i) a high 
specificity of integration into Exon 1 of the HPRT target site as 
well as (ii) a high codon optimized arginase RNA expression 
with substantial functional arginase enzyme activity in hiPSCs.
Directed differentiation of human pluripotent cells into 
hepatocyte-like cells
Using a previously published protocol,17
 we differentiated 
the corrected AD1, AD2, and AD3 hiPSCs, their uncorrected 
Figure 3 Measuring ArgO in AD hiPSCs. (a) Relative gene expression of ArgO, measured against glyceraldehyde 3­phosphate 
dehydrogenase (GAPDH), in AD1 uncorrected and corrected hiPSCs was measured by quantitative reverse transcription­polymerase chain 
reaction (qRT­PCR) in technical triplicate (n = 3). (b) After integration of ArgO in AD1 hiPSCs urea production was measured and compared 
with fetal liver (n = 2). Functionality experiments were performed in technical duplicate. (Data are represented as mean ± SD.) AD, arginase 
deficient; ArgO, codon optimized arginase; hiPSCs, human induced pluripotent stem cells; SD, standard deviation.
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counterparts, and control xc­HUF1 hiPSCs into hepatocyte­
like cells. After 21 days, we assessed expression of specific 
liver markers and assessed liver cell­specific functions of 
our derivatives. Morphology of the genetically modified AD1 
LEAPR hepatocyte­like cells resembled both that of their 
uncorrected counterparts (AD1 hepatocytes) and primary 
human adult hepatocytes (shown in Figure 4a; AD2 and AD3 
shown in Supplementary Figure S6a).
At the end of the final differentiation stage, we characterized 
the expression of hepatic markers in our derivatives. Similar 
to the primary adult hepatocyte control, LEAPR­corrected 
AD1, AD2, and AD3 derivatives stained positive for albumin 
(Figure 4a for AD1 and Supplementary  Figure S6a for AD2 
and AD3 respectively). The hepatocyte­like cells exhibited 
expression of AFP, whereas the primary adult hepatocyte 
control was essentially negative for AFP (Figure 4a). This 
Figure 4 Characterization of hepatocyte-like cells. (a) Derived uncorrected and corrected (gene added) AD1 hepatocyte­like were 
examined and morphology compared with primary adult hepatocytes in-vitro (Scale bars = 500 μm). (b) Hepatic markers were examined via 
RT­PCR in uncorrected and corrected AD1 hepatocyte­like cells: alpha 1­antitrypsin (AAT), AFP, human serum albumin (ALB), cytokeratin 
18 (CK18), carbamoyl phosphate synthase 1 (CPS1), cytochrome p450 3A4 (CYP3A4), factor IX (FIX), transferrin (TF), tryptophan 
2,3­dioxygenase (TDO2), and uridine diphosphate glucuronyltransferase (UDP-GT). (c) mRNA levels of ArgO in hepatocyte­like cells (left 
panel) was compared with both unmodified and modified AD hiPSCs (n = 3) and unmodified hepatocyte­like cells (n = 3). Urea production 
of corrected hepatocyte­like cells (right panel) was also examined. (See also Supplementary Figures S6ab, S4, S5) (Data are represented 
as mean ± SD.) AD, arginase deficient; ArgO, codon optimized arginase; hiPSCs, human induced pluripotent stem cells; RT­PCR, reverse 
transcription polymerase chain reaction; SD, standard deviation.
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observation is consistent with previous studies demonstrat­
ing that PSC­derived hepatocyte­like cells more closely 
mimic fetal as opposed to adult hepatocytes23; that is, mature 
hepatocytes lose AFP expression while more fetal­like hepa­
tocytes continue to express AFP. Therefore, we compared 
RNA expression of multiple hepatic­specific markers of the 
derivatives to a human fetal liver control. RT­PCR analysis 
showed that AD1, AD2, and AD3 hepatocyte­like cells all 
expressed hepatic functional genes including: ALB, AFP, 
AAT, CK18, CPS1, CYP3A4, FIX, TF, TDO2, and UDP-GT 
(Figure 4b for AD1 and Supplementary Figure S6b for AD2 
and AD3). Human primary adult hepatocytes and fetal liver 
were used as positive controls for the immunostaining and 
RT­PCR analysis, respectively.
Additionally, we assessed liver­specific functionality of 
both our genetically modified and unmodified AD1, AD2, and 
AD3 hepatocyte­like cells. At day 21, we measured glycogen 
storage via Periodic Acid­Schiff (PAS) staining of all hepatic 
derivatives. Similar to primary adult hepatocytes, corrected 
AD1, AD2, and AD3 hepatocyte­like cells stained positive by 
PAS (Figure 4a for AD1 and Supplementary Figure S6a for 
AD2 and AD3 respectively). These results demonstrate that 
genetic modification of hiPSCs with our LEAPR construct 
does not interfere with the capability of the cells to differenti­
ate into hepatocyte­like cells.
Evaluation of arginase expression and functionality in 
hepatocyte-like cells
We examined codon optimized arginase RNA expression 
and functionality in the hiPSC­derived hepatocyte­like cells 
to determine the maintenance of arginase expression after 
directed differentiation. After the final differentiation step, 
RNA was collected from LEAPR­corrected AD1, AD2, and 
AD3 hepatocyte­like cells; arginase levels were quantified 
and compared with both corrected hiPSC and fetal liver levels 
via qRT­PCR. Hepatic differentiation did result in a decrease 
in arginase RNA expression in all three LEAPR­corrected 
hepatocyte­like cell lines compared with undifferentiated 
hiPSCs (P < 0.0001 for AD1; P < 0.0002 for AD2 and AD3) 
(Figure 4c left panel for AD1 and Supplementary Figure S5 
for AD2 and AD3 respectively). However, despite the decline 
in RNA expression compared with hiPSCs, AD1, AD2, and 
AD3 hepatocyte­like cells maintained arginase levels of 27, 
39, and 36% of fetal liver Arg1 levels (AD1, AD2, and AD3 
respectively).
Next, we determined if targeted integration of the LEAPR 
construct affected expression of the wild type mutated argi­
nase and other endogenous urea cycle­specific genes in the 
hepatocyte­like cells, specifically, carbamoyl phosphate syn­
thase 1 (CPS1), which catalyzes the synthesis of carbamoyl 
phosphate from glutamine. We measured mRNA levels of 
CPS1 in both uncorrected and corrected hiPSCs and hepa­
tocyte­like cells (Supplementary Figure S7). Similar to wild 
type mutated arginase mRNA expression, CPS1 levels were 
significantly increased postdifferentiation in both uncorrected 
and corrected lines (P = 0.01 for AD1 uncorrected lines; 
P < 0.0001 for AD1 corrected, AD2 uncorrected and cor­
rected, and AD3 uncorrected and corrected lines). These 
data suggest that the increasing arginase expression with 
our LEAPR construct in the disease lines does not negatively 
impact the expression of other endogenous urea cycle­spe­
cific genes.
With the described decline in RNA expression, there was 
an expected postdifferentiation decline observed in ureagen­
esis of the LEAPR derivatives (P = 0.0004 for AD1; P < 0.001 
for AD2; P < 0.0007 for AD3 compared with corrected hiP­
SCs). Importantly, though, all three corrected hepatocyte­like 
cell lines maintained >40% of the level of urea production 
(i.e., arginase activity) of fetal liver (Figure 4c, right panel 
for AD1 and Supplementary Figure S5 for AD2 and AD3 
respectively).
Discussion
Chronic therapy for UCDs includes dietary restriction to limit 
nitrogen intake and pharmacological intervention with nitro­
gen scavenging drugs (e.g., phenylbutyrate). Such substrate 
restriction is commonly used for treating UCDs while it is 
somewhat effective, this is more prophylactic than curative 
and patients remain at risk for developing long­term neuro­
logical issues due to intermittent hyperammonemia. Gene 
and stem cell therapy have emerged as promising therapeu­
tic avenues to treat these disorders and prevent the develop­
ment of hyperammonemia­induced neurological injury.24–28
Stem cells, specifically hiPSCs, provide an almost inex­
haustible source of patient­specific cells that can undergo 
directed differentiation into various somatic cell types to be 
used for cellular replacement therapies.29–31 Due to their ther­
apeutic potential, considerable effort has been aimed into 
optimizing protocols to genetically modify these cells in order 
to model diseases and to use in potential cellular therapies.32 
However, despite the promise of utilizing genetically modified 
hiPSCs for therapeutic studies, the ability to efficiently deliver 
genes to targeted sites in hiPSCs is hampered by several 
challenges. Nonviral methods, such as chemical transfec­
tion or electroporation, and viral methods, via lentiviruses 
or adeno­associated viruses, all suffer from relatively low 
transfection and transduction efficiencies, transient expres­
sion, and off­target integration in the host hiPSC genome.25,32 
Recently, the development of highly specific CRISPRs and 
CRISPR­associated (Cas) systems to introduce genes into 
hiPSCs have begun to address many previous issues sur­
rounding genomic editing of stem cells. Unlike its prede­
cessors, such as zinc finger nucleases and transcription 
activator­like effector nucleases, CRISPR/Cas9 systems can 
be produced rapidly and introduced into specific target sites 
with increased accuracy.19,33,34 As such, recent studies have 
demonstrated highly efficient genetic correction of hiPSCs 
utilizing CRISPR/Cas9 for neural and muscular disorders.35
The goal of this study was to determine if integration of 
codon­optimized arginase into three genetically distinct 
patient­specific hiPSCs could produce in vitro enzyme func­
tion after differentiation into hepatocyte­like derivatives for 
potential use in cellular therapy for these patients. Previous 
gene therapy studies have demonstrated successful reversal 
of disease manifestations through either treatment of neona­
tal mice with a helper­dependent adenoviral vector24 or with 
adeno­associated virus­expressing arginase.36 In the former, 
the transient nature of expression led to loss of arginase 
Molecular Therapy—Nucleic Acids
iPSC Genomic Addition to Re-establish Ureagenesis
Lee et al.
8
function while in the later, long­term survival without neuro­
pathology was achieved; however, with the loss of episomal 
adeno­associated virus genomes, the level of arginase 
expression was low and therefore, the animals remained 
nitrogen vulnerable.7 However, these murine studies were 
able to determine that long­term survival36 with normal 
behavior and learning37 was possible and that only low levels 
of hepatic arginase activity, as low as 3.5–5%, were neces­
sary to prevent brain injury and/or death from hyperammo­
nemia or hyperargininemia.7 Here, we developed a CRISPR/
Cas9­based strategy to deliver a codon­optimized version 
of human arginase 1 into hiPSCs derived from patients with 
arginase deficiency. Arg1 was introduced into Exon 1 of the 
HPRT locus via a construct containing right and left homolo­
gous arms, the human elongation factor 1α promoter, a poly­
adenylation signal, and puromycin for selection (LEAPR), 
resulting in substantial arginase enzymatic activity in hiPSCs 
and in differentiated derivatives.
Cellular HPRT is an enzyme that catalyzes the conversion 
of hypoxanthine to inosine monophosphate and guanine to 
guanosine monophosphate in the nonessential purine sal­
vage pathway.38 Homozygous loss of HPRT function results 
in Lesch­Nyhan syndrome, which causes an overproduction 
of uric acid. However, in normal conditions, purine salvage 
and HPRT do not play a major role in cell growth and prolif­
eration39; in therapeutic administration of cells where HPRT 
is not functional in the large mass of HPRT­positive cells 
(such as the liver), it is believed that this loss will be incon­
sequential in purine metabolism. There are certainly desir­
able selective advantages of utilizing HPRT for integrated 
cell selection: HPRT­positive cells are sensitive to 6­thiogua­
nine (6­TG), killing cells by postreplicative mismatch repair40; 
additionally, this mechanism allows for secondary selection 
with 6­TG after HPRT locus disruption.41,42 As transfection 
efficiency of hiPSCs is inherently low, the incorporation of a 
dual selection method with puromycin and 6­TG allowed us 
to purify a population of hiPSCs that contained the integrated 
construct at the targeted site utilizing nucleofection to deliver 
CRISPR/Cas9 nickases and the LEAPR cassette. In culture, 
these corrected hiPSCs showed that they maintained proper 
morphology and pluripotency, and sequencing data and qRT­
PCR­based genomic integration quantification confirmed that 
the constructs integrated into the correct targeted site in a 
single HPRT allele with no off­target insertions and deletions 
at high unrelated probable sites. While the data demonstrate 
that a single X chromosome of each AD line is integrated with 
the donor construct, we did detect genetic mutations in the 
other allele of HPRT at the site of nuclease A and B activity.
Importantly, arginase was highly expressed in LEAPR­ 
corrected cells as shown by both qRT­PCR and in urea 
production from functional arginase activity. After directed 
differentiation of LEAPR­corrected hiPSCs to the hepatic lin­
eage, the hepatocyte­like cells were positive for albumin and 
α­fetoprotein, stored glycogen, and expressed multiple liver­
specific RNAs. To determine if differentiation affected expres­
sion and functionality of arginase in the hepatocyte­like cells, 
we quantified RNA levels and urea production for comparison 
with their hiPSC counterparts. While RNA levels of LEAPR­
derived arginase in hepatocyte­like cells were lower when 
compared with their hiPSC counterparts, functional arginase 
expression with urea production for all LEAPR­corrected 
hepatocyte­like cells remained, and at levels that were previ­
ously determined (with adeno­associated virus­based gene 
therapy) to be necessary for arginase­deficient mice to sur­
vive and be without neurodevelopmental abnormalities. As 
previous studies by others have shown a decline in transgene 
expression during differentiation with the use of the hEF1α 
promoter in embryonic stem cells,43 this in part may explain 
the decline in expression in the hepatocyte derivatives in this 
study. Additionally, comparison of wild type mutated arginase 
and CPS1, another urea cycle enzyme, demonstrated that 
LEAPR modification does not negatively affect the expres­
sion of endogenous promoters of urea cycle enzymes. In 
aggregate, however, these data demonstrate that genetic 
modification at the HPRT locus of the arginase­deficient lines 
had no deleterious effect on their pluripotent capability and 
overall “stemness”; were not altered by nucleofection, selec­
tion, or culture of the hiPSCs; and were able to be differenti­
ated into hepatocytes with restoration of arginase activity and 
ureagenesis.
Based on these data, integration of Arg1 via the LEAPR 
expression construct by targeting the HPRT locus demon­
strates the potential for restoring enzymatic activity in cells 
derived from hyperargininemic patients. Previously, we have 
shown in a murine model that with relatively low overall 
hepatic arginase activity establishing ureagenesis at 3.5–5% 
of normal led to long­term survival with controlled plasma argi­
nine and ammonia; however these animals remained nitro­
gen vulnerable due to the low level of arginase expression.7 
LEAPR­corrected hepatocyte­like cells across all three lines 
demonstrated functionality of at least 40% compared with 
fetal liver; while the hEF1α promoter­based expression did 
decline with cellular differentiation, arginase expression in our 
studies remains well above the minimum threshold needed for 
survival and adequate nitrogen metabolism determined from 
the prior murine arginase studies.7 While our present LEAPR 
construct contains a copy of the selection marker puromy­
cin, an aminonucleoside antibiotic, before clinical applicabil­
ity alteration of our donor construct to avoid integration of an 
antimicrobial resistance gene and its potential immunogenic­
ity would be required. This would be accomplished by altering 
our donor construct by adding flanking loxP sites to the puro­
mycin cDNA such that it could excised at the hiPSC stage 
prior to differentiation to the hepatocyte lineage.
Over the last 30 years, multiple studies in rodents have 
shown that adult hepatocyte transplantation can reverse liver 
failure and can correct various metabolic deficiencies of the 
liver.44,45 While clinical trials of hepatocyte transplantation 
have demonstrated the long­term safety of cellular admin­
istration, only partial correction of metabolic disorders in 
humans has ever been achieved.46,47 In part due to the lim­
ited availability of fresh donor hepatocytes of adequate qual­
ity, clinical trials, however, have been hampered and reports 
have been limited in general to case reports involving a few 
patients at most and generally with no untreated controls.48–51 
While attaining adequate engraftment will need further atten­
tion to make such therapies successful for patients with 
metabolic liver disorders, issues of cellular rejection should 
be greatly reduced45 with an hiPSC approach as described 
herein.
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In choosing this approach where cell availability and num­
bers of hepatocytes will not be a limitation, there are other 
important implications for treating more common monogenic 
disorders of the liver. The safe harbor of exon 1 of HPRT 
could be used in that the efficiency of homologous recom­
bination has been demonstrated here as well as the exog­
enous gene expression at this locus based on the hEF1α 
promoter. Targeted therapy of other liver­based disorders 
would be easily addressed by substitution of the arginase 
cDNA from the donor construct with one of the other enzyme 
cDNA sequences from another metabolic disorder.
This study presents an approach that can be utilized to 
integrate an optimized cassette into a universal site dis­
tant from proto­oncogenes in patient­specific hiPSCs to 
restore function of abnormal liver enzymes. While we have 
addressed the restoration and maintenance of transgene 
expression pre­ and postdifferentiation, additional studies are 
required to investigate the in vivo therapeutic efficacy of the 
corrected derivatives to maintain recovered arginase activity 
after cellular transplantation. Successful in vivo recovery of 
enzyme function by means of these strategies could benefit 
enzyme deficiencies of the urea cycle and other inborn errors 
of metabolism.
Materials and methods
In vitro derivation and culture of primary human dermal 
cells. The control human dermal fibroblast cell line (xc­
HUF1), obtained from UCLA Good Manufacturing Practice 
(GMP) facility,22 and two disease fibroblast lines (AD2 and 
AD3) used in this study were obtained from adult skin punch 
biopsy (after IRB approval and informed consent) and were 
cultured in methods previously published.11,20 One adult dis­
ease fibroblast line (GM00954, renamed AD1) was obtained 
from Coriell Institute for Medical Research (Camden, NJ). All 
procedures were approved by the Institutional Review Board 
(IRB #13­001469­AM­00002) and the Embryonic Stem Cell 
Research Oversight (ESCRO) (ESCRO #2010­010­04A) 
Committee of the University of California, Los Angeles and 
informed consent was documented from both patients.
All fibroblast lines were cultured in media consisting of 
Dulbecco’s modified Eagle medium nutrient mixture/F­12 
(DMEM/F­12) (Invitrogen, Grand Island, NY), 10% fetal 
bovine serum (FBS) (Invitrogen), 1× Glutamax (Invitrogen), 
1× minimum essential medium nonessential amino acid (Invi­
trogen) and 1× Primocin (InvivoGen, San Diego, CA). Cells 
were maintained in a 37°C 5% CO2 incubator. Media was 
changed every 1–2 days and cells were passaged with 0.05% 
trypsin­ethylenediamine tetraacetic acid (EDTA) (Gemini Bio­
Products, West Sacramento, CA).
In vitro derivation and culture of human stem cell lines. The 
control hiPSC line xc­HUF1 and the three disease hiPSC lines 
(AD1, AD2, and AD3) were developed by reprogramming 
from corresponding parental fibroblast lines via a lentiviral 
transduction of a stem cell cassette (STEMCCA) containing 
the reprogramming factors Oct4, Sox2, Klf4, and c­Myc.52
Fibroblasts were seeded at a confluency of 10,000 cells/
cm2 prior to transfection. After viral transduction, cells were 
maintained in a 37°C 5% CO2 incubator for 3 days in a defined 
media consisting of DMEM/F­12 (Invitrogen) supplemented 
with 20% Knockout Serum Replacement (Invitrogen), 1× Glu­
tamax (Invitrogen), 1× Minimal Essential Media NonEssential 
Amino Acids Solution (Invitrogen), 1× Primocin (InvivoGen), 
1× β­mercaptoethanol (Millipore, Billerica, MA), and 10 μg/ml 
basic fibroblast growth factor (bFGF) (Biopioneer, San Diego, 
CA). After 3 days, the cells were passaged with 0.05% trypsin 
EDTA (Gemini Bio­Products) onto a layer of mouse embryonic 
fibroblasts (GlobalStem, Rockville, MD) and maintained in cul­
ture up to 30 days until putative hiPSC colonies began to form.
All cells were transitioned to and subsequently maintained 
in feeder­free culture conditions consisting of reduced growth 
factor Matrigel (BD Biosciences, San Jose, CA) and a 50:50 
mix of mTeSR1 media (StemCell Technologies, Vancouver, 
BC, Canada) and Nutristem (Stemgent, San Diego, CA) 
supplemented with 1× Primocin (InvivoGen) and 10 μg/ml 
bFGF. Cells were mechanically passaged every 4 to 5 days, 
depending on confluency and colony size. To passage the 
cells, pulled glass pipettes were used to cross­hatch the 
colonies and to lift the pieces gently for transfer onto new 
Matrigel­coated plates.
DNA delivery by nucleofection. Cells were prepared for 
nucleofection by aspirating the media from each well and 
replacing with 2 ml of mTeSR/Nutristem media supplemented 
with 10 μmol/l ROCK inhibitor (BioPioneer, San Diego, CA). 
After 1 hour, the media was again aspirated and replaced 
with 1 ml Stempro Accutase (Life Technologies, Carls­
bad, CA) and incubated at 37ºC for 4–6 minutes in 1–2 ml 
of mTeSR1/Nutristem media supplemented with 10 μmol/l 
ROCK inhibitor in each well to neutralize the Accutase. Cells 
were then washed and gently scraped into suspension. The 
cell suspension was transferred to a sterile 15 ml conical tube 
and centrifuged for 5 minutes at 80g. The supernatant was 
aspirated and the cells were resuspended in an appropriate 
volume of mTeSR1/Nutristem media with ROCK inhibitor. 10 
μl of the resuspended sample was removed and counted by 
hemocytometer. Samples planned for nucleofection were 
prepared as 800,000–1 million cells each. Aliquots were cen­
trifuged for 5 minutes at 80g. Supernatant were aspirated 
and the cells were resuspended in 100 μl of nucleofection 
solution (Lonza, Walkersville, MD) and placed into nucleofec­
tion cuvettes. (Care was taken to carefully resuspend cells 
to maximize the amount of single cells in suspension and 
to minimize cell death due to excessive mechanical stress). 
1–2 μg of each DNA vector was added and mixed into the 
nucleofection solution. Controls, 1–2 μg of pMAX­GFP, which 
is included in the kit, were added to one aliquot of each 
cell solution. The samples were then securely placed into 
an Amaxa Nucleofector II (Lonza) and nucleofected using 
the B­016 program to facilitate cellular DNA vector uptake. 
The cells were then pipetted into either previously prepared 
Matrigel­coated plates or directly onto previously prepared 
plates of mouse embryonic fibroblasts. 72 hours after plating, 
mTeSR1/Nutristem media was supplemented with 1 μg/ml of 
puromycin for an additional 72 hours. Following puromycin 
selection, cells were cultured in mTeSR1/Nutristem media 
without puromycin. Colonies were expanded until large 
enough to isolate by mechanical passaging.
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Hepatocyte differentiation of iPSCs. To begin hepatocyte dif­
ferentiation, hiPSCs were passaged at 90% confluency. The 
next day, the differentiation protocol began as previously 
published.17 Briefly, hiPSCs were incubated for 24 hours with 
Roswell Park Memorial Institute (RPMI) 1640 medium (Life 
Technologies, Carlsbad, CA), and supplemented with 0.5 mg/
ml bovine serum albumin (BSA; Sigma­Aldrich, St. Louis, 
MO), 100 ng/ml Recombinant Human Activin A (Peprotech, 
Rocky Hill, NJ), and 1× Primocin (Invivogen). On days 2 and 
3, 0.1% and 1% insulin­transferrin­selenium (Life Technolo­
gies) were added to the previous supplemented RPMI 1640 
medium, respectively. On day 4, hiPSCs were cultured with 
Hepatocyte Culture Medium (HCM) (consisting of HBM Basal 
Medium and HCM SingleQuot Kit) (Lonza) supplemented 
with 30 ng/ml Recombinant Human Fibroblast Growth Fac­
tor­4 (FGF­4) (Peprotech), 20 ng/ml Bone Morphogenetic 
Protein­2 (BMP­2) (Peprotech), and 1× Primocin (Invivo­
gen) for 4 days. The differentiated cells were then cultured in 
HCM containing 20 ng/ml Recombinant Human Hepatocyte 
Growth Factor (HGF), 20 ng/ml Recombinant Human Kera­
tinocyte Growth Factor (KGF), and 1× Primocin (Invivogen) 
for 6 days, and then in HCM supplemented with 10 ng/ml 
Recombinant Human Oncostatin M (OSM) (R&D Systems, 
Minneapolis, MN), 0.1 μmol/l dexamethasone (Sigma), and 
1× Primocin (Invivogen) for the following 5 days. For the last 
3 days of the hepatic differentiation, the cells were cultured 
in DMEM/F:12 (Life Technologies) supplemented with 1× N2, 
1× B27, 1× GlutaMAX (Life Technologies), 1× NEAA (Life 
Technologies), 0.1 mmol/l β­mercaptoethanol (Life Technolo­
gies), and 1× Primocin (Invivogen). All media and supple­
ments were filtered prior to use with a 0.22 micron filter and 
media was changed daily.
Immunocytochemistry. Cells were washed with phosphate 
buffered saline (PBS) and fixed with 4% paraformaldehyde 
(Polysciences, Warrington, PA) in 1× PBS for 15 minutes 
prior to staining. When necessary, samples were permea­
bilized in 1% Triton X­100 (Sigma­Aldrich, St. Louis, MO) 
in PBS for 1 hour at room temperature. Subsequently, all 
samples were blocked with 5% goat serum (Sigma) in PBS 
for 1 hour at room temperature. Primary antibodies were 
diluted to working concentrations in 5% goat serum; cells 
were incubated with the primary antibody overnight in 4°C. 
After incubation, cells were washed three times with PBS at 
5 minutes per wash. Secondary antibodies were diluted in 
5% goat serum and cells were incubated for 1 hour at RT. 
Cells were washed three times with PBS and incubated with 
1 × 4,6­diamidino­2­2­phenylindole (DAPI; Thermo, Waltham, 
MA) for 7 minutes. Fluorescence images were captured with 
an Axiocam MR Monocolor Camera and AxioVision Digital 
Image Processing Software (Axio Observer Inverted Micro­
scope; Carl Zeiss, Jena, Germany). The primary and second­
ary antibodies used for hiPSC and hepatocyte­like cells are 
listed in Table 1.
Teratoma formation and analysis. Teratomas for the control 
and disease hiPSC lines were generated by injecting 1 × 106
 
cells (resuspended in Matrigel (BD Biosciences)) subcutane­
ously into both hind limbs of male severe combined immu­
nodeficient (SCID) mice (Charles River Laboratories, San 
Diego, CA). Tumors were harvested roughly 1–1.5 months 
after injection and fixed in 4% paraformaldehyde. Tissues 
were routinely processed and paraffin­embedded followed by 
staining with hematoxylin and eosin (H&E). All animal experi­
ments adhered to policies set by the UCLA Animal Research 
Committee and the UCLA Division of Laboratory Animal 
Medicine (Protocol #2006­119­22).
Karyotype analysis. The hiPSCs were cultured to 95–99% 
confluency in 25 cm2 flasks and delivered to Cell Line Genet­
ics (Madison, WI) for G­band karyotyping analysis.
Reverse transcription PCR. RNA was extracted from primary 
fibroblasts, hiPSCs, and hepatocyte­like cells with a Roche 
High Pure RNA Isolation Kit (Roche Applied Sciences, 
Indianapolis, IN) and 10 ng–1 μg was reversed transcribed 
to cDNA with the Transcriptor First Strand cDNA synthesis 
kit (Roche Applied Sciences) following the manufacturer’s 
instructions. Primers were designed in NCBI/Primer­Blast 
and synthesized by Valugene (San Diego, CA) and are listed 
in Table 2. RT­PCR was performed with 25 ng of cDNA from 
each sample and each reaction was prepared with 12.5 μl 2× 
KAPA Fast Genotyping Mix (Kapa Biosystems, Wilmington, 
MA) and with 10 μmol/l forward and reverse primers and was 
run on a LightCycler 480 Real­Time PCR System (Roche 
Applied Sciences). Gels were made with 2% agarose (Bio­
Rad Laboratories, Hercules, CA) and 1× SYBR Safe DNA 
Gel Stain (Life Technologies) in tris­acetate­EDTA (TAE) buf­
fer and run on a PowerPac Basic Power Supply (Bio­Rad) at 
90 V for 30 minutes.
Table 1 Primary and secondary antibodies used to demonstrate pluripotency and to characterize hepatocyte­like cells
Primary antibody Secondary antibody
Reference Dilution Isotype Reference Dilution
Oct-3/4 SCBT, Santa Cruz, CA, SC­5279 1:100 Donkey anti­Rabbit IgG Alexa Fluor 546 Life Technologies, Carlsbad, CA, A­10036 1:250
Nanog Abcam, Cambridge, MA, ab80892 1:100 Goat anti­Rabbit IgG (H+L) Alexa Fluor 488 Life Technologies, A­11008 1:500
SSEA-3 Millipore, mab4303 1:200 Goat anti­Rat IgM Alexa Fluor 594 Life Technologies, A­21213 1:500
SSEA-4 Millipore, mab4304 1:200 Goat anti­Mouse IgG (H+L) Alexa Fluor 488 Life Technologies, A­11001 1:500
TRA-1–60 Millipore, mab4360 1:200 Goat anti­Mouse IgM Alexa Fluor 488 Life Technologies, A­20142 1:500
TRA-1–81 Millipore, mab4381 1:200 Goat anti­Mouse IgM Alexa Fluor 488 Life Technologies, A­20142 1:500
Albumin R&D Systems, Minneapolis,  
MN mab1455
1:50 Goat anti­Mouse IgG (H+L) Alexa Fluor 488 Life Technologies, A­11001 1:250
Alpha-  
fetoprotein
Life Technologies, 18­0003 1:50 Goat anti­Mouse IgG (H+L) Alexa Fluor 488 Life Technologies, A­11001 1:250
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Quantitative RT-PCR. Total RNA was isolated from cultures 
with a Roche High Pure RNA Isolation Kit (Roche Applied 
Sciences) and 250 ng–1 μg was reverse transcribed to 
cDNA utilizing a Transcriptor First Strand cDNA Synthesis Kit 
(Roche Applied Sciences). Primers for endogenous arginase 
and human codon­optimized arginase and probes (designed 
from the Roche Universal Probe Library) were synthetized at 
Valuegene (Table 3). Quantitative PCR relative gene expres­
sion experiments were performed with 10 ng of cDNA on a 
LightCycler 480 Real­Time PCR System (Roche) and data 
was analyzed with LightCycler 480 Software (release 1.5.0.). 
Triplicate experimental samples were paired using the all­
to­mean pairing rule ΔCt value calculation with GAPDH for 
advanced relative quantification.
Cloning and gene optimization. pUC18­HPRTx1­LHA­
hEF1α­ArgO­IRES­PAC­HPRTx1­RHA was cloned by PCR of 
HPRTx1 (Exon 1)­RHA(Right Homologous Arm) with primers 
5′­HPRT­RHA­NotI (GCATGCGGCCGCCAGTCAGCCCGC­
GCGCC) and 3′­HPRT­RHA­PstI (CGATCTGCAGCCTGC­
CGCCCTCGCGT) and restriction enzyme digested with NotI 
and PstI. HPRTx1­LHA (Left­Homologous­Arm) was synthe­
sized by GeneWiz, removed and isolated from pUC57­Kan 
by digestion with EcoRI and XbaI. hEF1α­ArgO­IRES­PAC 
was removed and isolated from pRRL­hEF1α­ArgO­IRES­
PAC with XbaI+NotI digest. Two synthetic polyadenylation 
sequences53 were inserted 3′ of HPRTx1­LHA and 5′ of 
HPRTx1­RHA by cutting and inserting the sequences with 
SpeI and NotI, respectively. Oligonucleotides were synthe­
sized by ValueGene and annealed together to create inserts 
for cloning. Finally, all inserts were ligated together with 
pUC18 digested by EcoRI and PstI. DNA was introduced into 
cells by nucleofection (see Supplementary Experimental Pro­
cedures for details).
Human codon optimized arginase (ArgO) was developed 
by running the amino acid sequence of Arg1 through Gene 
Designer 2.0 software (DNA2.0, Menlo Park, CA) against the 
homo sapiens codon usage table. Once the initial sequence 
was produced, it was run through NetGene2 (http://www.cbs.
dtu.dk/services/NetGene2/) to find any cryptic splice sites. 
This sequence was then checked for any long repeats in Oli­
gonucleotides Repeat Finder (http://wwwmgs.bionet.nsc.ru/
mgs/programs/oligorep/InpForm.htm). Any variations needed 
to delete splice sites or long repeats were silent mutations 
that used the next most common codon in the Homo sapiens 
codon usage table.
Junction PCR and sequencing analysis. To verify targeted 
integration of our donor vector in corrected hiPSCs, each 
5′ and 3′ junction of the integrated vector was analyzed by 
PCR and DNA sequencing. Reactions were prepared with 
genomic DNA, 12.5 μl of Phusion High­Fidelity PCR Master 
Mix (New England BioLabs, Ipwich, MA), 10.25 μl of water, 
and 1.25 μl of forward and reverse primers for the 3′ and 5′ 
ends of Exon 1 of HPRT (Table 4).
For sequencing, PCR bands were extracted and purified 
using the Wizard SV Gel and PCR Cleanup System (Pro­
mega, Madison WI) and the purified products were sent to 
Laragen (Culver City, CA) for sequencing analysis.
Off target analysis. To identify potential introduced muta­
tions at other regions in the genome, off­target binding/cut­
ting of the DNA by the CRISPR/Cas9 nucleases resulting in 
insertions or deletions was analyzed at the predicted most 
common sites for each CRISPR/cas9 nickase as deter­
mined by the MIT CRISPR Design website (http://www.
crispr.mit.edu). Each corresponding gDNA region sequence 
was downloaded from the PubMed genebank. PCR prim­
ers were designed using the ThermoFisher primer designer 
(http://www.thermofisher.com/oligoperfect.html). Appropriate 
primers were synthesized by Integrated DNA Technologies 
(Coralville, IA) to amplify each off­target region. For par­
ticularly GC­rich regions, 5% dimethylsulfoxide (DMSO) or 
Betaine (Sigma) was added. The region on the other HPRT 
allele was amplified using the same 5′F and 3′R junction 
PCR primers as was used for junction PCR analysis. Each 
potential off­target region was amplified by PCR from both 
the parental and genetically modified gDNA samples of AD1 
Table 2 List of reverse transcription­polymerase chain reaction (RT­PCR) 
forward (F) and reverse (R) primer sets for hepatic markers
Gene Primer sequence Amplicon
AAT F: 5′ AAGGACACCGAGGAAGAGGA 3′  
R: 5′ CACCCCTGAAGCTCTCCAAG 3′
393
ALB F: 5′ ACCCCAAGTGTCAACTCCAA 3′  
R: 5′ CTGAAAAGCATGGTCGCCTG 3′
224
CK18 F: 5′ ACACAGTCTGCTGAGGTTGG 3′  
R: 5′ GCCTCCAGCTTGACCTTGAT 3′
275
CPS1 F: 5′ TTTAGGGCAATGGCTACAGG 3′  
R: 5′ GTTCTGCAAGAGCTGGGTTC 3′
541
CYP3A4 F: 5′ GGTGGTGAATGAAACGCTCAG 3′  
R: 5′ ACACACCCTTTGGAAGTGGACC 3′
243
FIX F: 5′ TGGAGATCAGTGTGAGTCCAAT 3′  
R: 5 ‘ACATGGAAATGGCACTGCTGG 3′
256
GAPDH F: 5′ TGAAGGTCGGACTCAACGGATTTGGT 3′  
R: 5′ CATGTGGGCCATGAGGTCCACCAC 3′
983
TDO2 F: 5′ TGGAGACGATGACAGCCTTG 3′  
R: 5′ AGCAGGAAAAGACACTTCTGGA 3′
214
TF F: 5′ ATTACGTCAACAGCAGCACCT 3′  
R: 5′ GCTGTAGGGAAAGACCAGACG 3′
533
UDP-GT F: 5′ GTGTCCCATGCTGGGAAGAT 3′  
R: 5′ CTGACGGACCCTTTCCTTCC 3′
394
AAT, alpha 1­antitrypsin; ALB, human serum albumin; CK18, cytokeratin 18; 
CPS1, carbamoyl phosphate synthase 1; CYP3A4, cytochrome p450 3A4; 
FIX, factor IX, GAPDH, glyceraldehyde 3­phosphate dehydrogenase; TF, 
transferrin; TDO2, tryptophan 2,3­dioxygenase; UDP-GT, uridine diphosphate 
glucuronyltransferase.
Table 3 List of reverse transcription­quantitative polymerase chain reaction 
(RT­qPCR) forward (F) and reverse (R) primer sets for wild type Arginase 1 
(Arg1) and the human codon optimized arginase (ArgO), carbamoyl­phos­
phate synthetase 1 (CPS1), and glyceraldehyde 3­phosphate dehydrogenase 
(GAPDH)
Gene Primer sequence Amplicon Probe
ARG1 WT F: 5′ CAGGATTAGATATAATGGAAGTGAACC 3′ 
R: 5′ CTGCTGTGTTCACTGTTCGAG 3′
78 60
ArgO F: 5′ AAGGTGATGGAGGAGACATTG 3′  
R: 5′ CGTCAACATCGAAGGACAGA 3′
76 69
CPS1 F: 5′ CAAGTTTTGCAGTGGAATCG 3′;  
R: 5′ ACGGATCATCACTGGGTAGC 3′
74 74
GAPDH F: 5′ GCTCTCTGCTCCTCCTGTTC 3′;  
R: 5′ ACGACCAAATCCGTTGACTC 3′
115  60
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using the Phusion PCR Master Mix (ThermoFisher). PCR 
conditions were set according to manufacturer recommenda­
tions: (i) 98°C 30 seconds, (ii) 98°C 10 seconds, (iii) 57°C 
30 seconds, (iv) 72°C 1 minute, Repeat 2–4 35×, (v) 72°C 5 
minutes, and (vi) 4°C hold using Phusion high­fidelity PCR 
master mix (ThermoFisher). PCR products were run on a 1% 
agarose gel for ~20 minutes at 100 V. Bands were extracted 
using the Wizard SV Gel and PCR Cleanup System, followed 
manufacturer protocol and were sequenced by Laragen.
To also determine if both HPRT alleles were integrated with 
the LEAPR construct, we performed quantitative real time 
PCR (ArgO, gGAPDH, and gHPRT) of each AD line know­
ing that AD1 and AD3 were XX and AD2 was XY (Table 5). 
Knowing this, we reasoned that we should see twice as much 
gHPRT in AD1 and AD3 compared with AD2 (Supplementary 
Figure S2, top). In addition, we reasoned that we should see 
the same amount of ArgO expression in all three AD lines 
relative to GAPDH (Supplementary Figure S2, middle). 
Finally, if only one allele was integrated we should detect half 
as much ArgO expression in AD1 and AD3 compared with 
AD2, relative to HPRT (i.e., 1 copy of ArgO per two copies of 
HPRT in AD1 and AD3 compared with 1 copy of ArgO per one 
copy of HPRT in AD2) (Supplementary Figure S2, bottom).
Functional assay for arginase activity. Arginase activity was 
measured in cell lysates. 2 × 106–4 × 106 cells were pelleted 
by low­speed centrifugation and frozen for each sample. 
Cell pellets were lysed at 20,000 cells/μl in lysis buffer. Pri­
mary tissue sample controls were homogenized with 40 μl 
of lysis buffer/mg of tissue. Lysis buffer was prepared with 
0.1% Triton X­100 and 1× HALT protease inhibitor cocktail 
(Thermo) and urea production was measured as previously 
performed.36,54 Briefly, samples were centrifuged at 100g for 
5 minutes at 4°C and the supernatant was collected. An acti­
vated mixture, consisting of 12.5 μl of 50 mmol/l Tris­Cl (pH 
7.5), 12.5 μl of 10 mmol/l MnCl, and 25 μl of the supernatant 
was incubated at 56°C for 10 minutes. 2.5 μl of the activated 
mixture was added to 25 μl of 0.5 mol/l arginine (pH 9.7) and 
incubated at 37°C for 1 hour. After incubation, 72.5 μl ddH2O 
was added to bring the final volume to 100 μl. 400 μl of an 
acid mixture, consisting of one part H2SO4 (95%), three parts 
H3PO4 (85%), and seven parts ddH2O, in addition to 25 μl of 
9% isonitrosopropiophenone (ISPF) in ethanol, was added to 
samples and urea standards. Urea standards were prepared 
at 9.3, 18.7, 37.5, 75, 150, and 300 μg/ml in ddH2O. The final 
mixture was incubated at 100°C for 45 minutes. After incu­
bation, samples were cooled to room temperature and pro­
tected from light for 10 minutes. 200 μl of each sample was 
aliquoted in duplicate and measured at an optical density of 
540 nm in a 96­well plate in a plate reader (Bio­Rad).
Sequencing analysis. Fibroblasts were cultured in 25 cm2 
flasks and delivered to GeneDx (Gaithersberg, MD) for com­
plete Arg1 gene sequencing and mutation analysis. Mutations 
were analyzed in hiPSC and hepatocyte progeny in the UCLA 
Orphan Disease lab by PCR followed by Sanger sequencing. 
Select regions of the Arg1 gene were amplified by PCR using 
standard conditions (95° for 2 minutes (1 cycle)); 94° for 30 
seconds, 60° for 30 seconds, 72° for 1 minute (35 cycles); 72° 
for 3 minutes (1 cycle); hold at 10°). Primer sequences for the 
c.61C>T variant were as follows: (5′­TTTGCACAAACTACTTG 
TTCACTG­3′; 5′­TCAGAGTGGGGAGGAAATCA­3′). Primers 
for the c.365G>A variant were as follows: (5′­AAAACCAA 
GTGGGAGCATTG­3′; 5′­CCTTCCACCTCCTGAATGTC­3′). 
Primers for the c.709G>A variant were as follows: (5′­CATG 
AAATAATGGGTTGCTACTTTT­3′; 5′­TTGCTTCTCTATTACC 
TCAGATTGTT­3′). Primers for the c.892G>C variant were as 
follows: (5′­CCATCGGTTACTACCTTTTTCTG­3′; 5′­TCTG 
AAAGAACAAGTCTTTAGAAGG­3′). An aliquot of each PCR 
product was confirmed by gel electrophoresis based on its 
predicted amplicon size. The rest of the PCR product was 
purified using the QIAquick PCR purification kit (Qiagen) 
and subjected to bidirectional sequencing using ABI BigDye 
v3.1 terminators on an ABI 3130xl genetic analyzer (Applied 
Biosystems, Foster City, CA). The sequence traces at each 
location were manually analyzed for the presence of a vari­
ant using the SequenceScanner v.1 software (Applied Bio­
systems) in comparison to the GenBank reference sequence 
NM_000045.3.
Statistical analysis. All collected data was analyzed with 
the SPSS (Armonk, NY) statistical package (Version 21.0). 
Results were expressed as mean ± standard deviation (SD) 
and P­values were determined using a one­way analysis of 
variance (ANOVA) to examine significance across compari­
sons. Error bars represent SD.
Supplementary material
Figure S1. Integration of LEAPR cassette in AD2 and AD3 
hiPSCs.
Figure S2. Determining single integration of LEAPR into 
HPRT locus in corrected hiPSCs.
Figure S3a. Off target analysis of nickase A for potential in­
sertions or deletions.
Figure S3b. Off target analysis of nickase B for potential in­
sertions or deletions. 
Figure S4. Measuring ArgO in AD2 and AD3 hiPSCs.
Figure S5. Measuring ArgO in AD2 and AD3 hepatocyte­like 
cells.
Table 4 List of reverse transcription­polymerase chain reaction (RT­PCR) 
forward (F) and reverse (R) primer sets for the 3′ and 5′ junctions of Exon 1 
of the hypoxanthine­guanine phosphoribosyltransferase (HPRT) gene
Gene Primer sequence
HPRT 5′ F: 5′ CCTGATCTGGGTGACTCTAGGACT 3′  
R: 5′ CACGACATCACTTTCCCAGTTTAC 3′
HPRT 3′ F: 5′ TGCAAGAACTCTTCCTCACG 3′  
R: 5′ GCATCTCCATAAAGATGAACTACAGTGTGCAAAAC 3′
Table 5  List of reverse transcription­quantitative polymerase chain reaction 
(RT­qPCR)­based genomic integration analysis forward (F) and reverse (R) 
primer sets for genomic hypoxanthine­guanine phosphoribosyltransferase 
(gHPRT) and genomic glyceraldehyde 3­phosphate dehydrogenase (gGAP­
DH)
Gene Primer sequence Amplicon Probe
gHPRT F: 5′ CGGTAGAGGAGAGGGTAGAGC 3′ 
R: 5′ ACAGGACTGGCAAAGGTGAG 3′
62 65
gGAPDH F: 5′ GCCTCAAGATCATCAGGTGAG 3′  
R: 5′ CAGGGGAGCGTGTCCATA 3′
76 64
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Figure S6a. Characterization of AD2 and AD3 hepatocyte­
like cells.
Figure S6b. Characterization of AD2 and AD3 hepatocyte­
like cells.
Figure S7. Measuring Wild­type Arg1 and CPS1 levels in un­
corrected and corrected hiPSCs and hepatocytes.
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